284 related articles for article (PubMed ID: 17108883)
41. Clinicopathological changes of uterine leiomyomas after GnRH agonist therapy.
Grigoriadis C; Papaconstantinou E; Mellou A; Hassiakos D; Liapis A; Kondi-Pafiti A
Clin Exp Obstet Gynecol; 2012; 39(2):191-4. PubMed ID: 22905461
[TBL] [Abstract][Full Text] [Related]
42. Clinical applications of GnRH agonists in gynaecology.
Preutthipan S
J Med Assoc Thai; 1993 Jan; 76 Suppl 1():11-8. PubMed ID: 8113648
[TBL] [Abstract][Full Text] [Related]
43. New approaches to the management of fibroids.
Shaw RW
Curr Opin Obstet Gynecol; 1991 Dec; 3(6):859-64. PubMed ID: 1818725
[TBL] [Abstract][Full Text] [Related]
44. A clinician's guide to the use of gonadotropin-releasing hormone analogues in women.
Moghissi KS
Medscape Womens Health; 2000 Jan; 5(1):5. PubMed ID: 10792849
[TBL] [Abstract][Full Text] [Related]
45. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
46. [Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix].
Felberbaum RE; Ludwig M; Diedrich K
Contracept Fertil Sex; 1999 Oct; 27(10):701-9. PubMed ID: 10605180
[TBL] [Abstract][Full Text] [Related]
47. [Preoperative treatment with GnRH analogs in hysterectomy].
Serrao L; Brizzi C; Primiero FM
Clin Ter; 1994 Nov; 145(11):403-6. PubMed ID: 7889725
[TBL] [Abstract][Full Text] [Related]
48. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
49. The facts about fibroids. Presentation and latest management options.
Christiansen JK
Postgrad Med; 1993 Sep; 94(3):129-34, 137. PubMed ID: 8361939
[TBL] [Abstract][Full Text] [Related]
50. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
Kawahara N; Kawaguchi R; Yamamoto K; Nishikawa K; Matsuoka M; Maehana T; Fukui Y; Yamanaka S; Sugimoto S; Iwai K; Yamada Y; Kurakami H; Hirata T; Takashima R; Suzuki S; Asada K; Kasahara M; Kimura F
Trials; 2024 Jan; 25(1):68. PubMed ID: 38243317
[TBL] [Abstract][Full Text] [Related]
51. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
52. [The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex)].
Ivanov S; Ivanov S
Akush Ginekol (Sofiia); 1998; 37(4):25-6. PubMed ID: 10360048
[TBL] [Abstract][Full Text] [Related]
53. [Directions of future research on GnGH analogs in the treatment of endometriosis and uterine fibromyoma].
Morini A; Aleandri V; Cantonetti G; Benagiano G
Minerva Ginecol; 1993 Oct; 45(10):455-65. PubMed ID: 8278076
[TBL] [Abstract][Full Text] [Related]
54. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist.
Kettel LM; Murphy AA; Morales AJ; Rivier J; Vale W; Yen SS
Fertil Steril; 1993 Oct; 60(4):642-6. PubMed ID: 8405517
[TBL] [Abstract][Full Text] [Related]
55. [GnRH analogues for the treatment of fibroids].
Murillo EO; Cano A
Med Clin (Barc); 2013 Jul; 141 Suppl 1():35-9. PubMed ID: 24314566
[TBL] [Abstract][Full Text] [Related]
56. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
57. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
Neblett MF; Stewart EA
Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
[TBL] [Abstract][Full Text] [Related]
58. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
[TBL] [Abstract][Full Text] [Related]
59. GnRH analogues--agonists and antagonists.
Padula AM
Anim Reprod Sci; 2005 Aug; 88(1-2):115-26. PubMed ID: 15955640
[TBL] [Abstract][Full Text] [Related]
60. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
